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Fetal therapies undertaken to improve fetal outcome or
to optimize transition to neonate life often entail some
level of maternal, fetal, or neonatal risk. A fetal therapy
center needs access to resources to carry out such
therapies and to manage maternal, fetal, and neonatal
complications that might arise, either related to the
therapy per se or as part of the underlying fetal or

maternal condition. Accordingly, a fetal therapy center
requires a dedicated operational infrastructure and
necessary resources to allow for appropriate oversight
and monitoring of clinical performance and to facilitate
multidisciplinary collaboration between the relevant
specialties. Three care levels for fetal therapy centers
are proposed to match the anticipated care complexity,
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with appropriate resources to achieve an optimal outcome at an institutional and regional level. A level I fetal
therapy center should be capable of offering fetal
interventions that may be associated with obstetric risks
of preterm birth or membrane rupture but that would be
very unlikely to require maternal medical subspecialty or
intensive care, with neonatal risks not exceeding those of
moderate prematurity. A level II center should have the
incremental capacity to provide maternal intensive care
and to manage extreme neonatal prematurity. A level III
therapy center should offer the full range of fetal
interventions (including open fetal surgery) and be able
manage any of the associated maternal complications
and comorbidities, as well as have access to neonatal and
pediatric surgical intervention including indicated surgery for neonates with congenital anomalies.
(Obstet Gynecol 2022;139:1027–42)
DOI: 10.1097/AOG.0000000000004793

F

etal therapy, performed for the benefit of the fetus
and neonate, has evolved markedly over the past
three decades.1,2 This is reflected in the increasing
membership of fetal therapy centers in the North
American Fetal Therapy Network and by the number
and complexity of interventions cumulatively performed at these centers.3,4 All fetal interventions,
whether medical or surgical, are by definition performed on a pregnant individual before separation
of the fetus from the placenta at birth. As such, they
may entail maternal risks in either the current or
future pregnancies, as well as fetal or neonatal risks.
Although this document refers to fetal interventions,
recommendations are intended to prioritize safety for
both the pregnant individual and their fetus or neonate based on the available evidence.
To perform any fetal intervention, provide all the
associated care needs, address any potential risks, and
assess outcomes, a fetal therapy center requires a
dedicated operational infrastructure, which encourages and facilitates the close collaboration of health
care professionals from maternal, fetal, nursing, anesthetic, and pediatric specialties.5–7 Several of these
specialties, specifically obstetrics and maternal–fetal
medicine, pediatric surgery, and neonatology,
already have established levels of care.8–10 These are
based on the guiding principle of matching resources
with the anticipated complexity of care to achieve
optimal outcomes at an institutional and regional
level.8–11 These care levels are independently assigned for each of these specialties and may not
coexist at the same level at a single institution.
Guidelines issued by the American College of
Obstetricians and Gynecologists (ACOG), the Society

1028

Baschat et al

Care Levels for Fetal Therapy Centers

for Maternal-Fetal Medicine (SMFM), and American
Academy of Pediatrics have outlined the general operational infrastructure necessary for centers to perform
fetal diagnostic and therapeutic procedures but have
not stratified these guidelines by the risk profile of
individual interventions.

GOAL
The purpose of this document is to propose levels of
care for fetal therapy centers based on the anticipated
complexity of an intervention for both pregnant
individuals and their neonates. Our recommendations
will also consider the obstetric, neonatal, pediatric
(medical and surgical), and ethical care resources that
should be in place to support such fetal interventions.
Our guiding principle is to provide maternal safety
and autonomy while also addressing the anticipated
care needs of the fetus and neonate.

FETAL INTERVENTIONS AND THE PRACTICE
OF FETAL THERAPY
The goal of fetal therapy may be to achieve a prenatal
cure, attenuate or improve sequelae for the infant, or
optimize the transition to postnatal life. When presented with a prenatal diagnosis, a pregnant individual
may choose to pursue expectant management, fetal
therapy, pregnancy termination, active neonatal care,
or palliation.12–17 It is the duty of the fetal therapy
center to support those decisions with the appropriate
level of care, regardless of the management choice.
A fetal therapy center must provide a pregnant
individual with an understanding of the fetal condition
and the relative maternal and fetal risks and benefits
of any proposed intervention when considering management options. The ability to appropriately counsel
patients relies on diagnostic capabilities that enable an
estimate of fetal risk based on an accurate prenatal
diagnosis and an understanding of the natural history
of the disease and its overall prognosis.
The risks of any fetal intervention depend on the
1) technical details of the procedure, including its
complexity, fetal status, degree of compromise, and
gestational age; 2) presence of maternal comorbidities
(eg, high body mass index [BMI, calculated as weight
in kilograms divided by height in meters squared],
obstetric risk factors for preterm birth, or membrane
rupture; and 3) operator and center experience.18–27
A comprehensive maternal assessment of psychosocial, familial, social, moral, religious, ethical, and
financial influences are elements to be considered in
the planning of the patient’s care.28,29 Risk–benefit
assessment will differ according to the specific intervention and by practitioner and fetal therapy center. If
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Medical director of fetal therapy center: direction and oversight of all fetal therapy operations
Nursing director of fetal therapy center: direction and oversight of all fetal therapy care
Multidisciplinary group of caregivers: direction
and oversight of disease-specific care paths and
therapies through multidisciplinary input; implementation of interventions through a predefined
team approach
Regular (at least monthly) multidisciplinary
patient care case conferences: planning and reviewing patient care and outcomes
Accredited diagnostic services

Prenatal ultrasonography, magnetic resonance
imaging, and fetal echocardiography: accurate diagnosis of fetal condition and monitoring of therapy
Genetics: diagnosis and counseling regarding
genetic diseases

Access to reference laboratory and pathology
services: chemistry, hematology, immunology, histology, metabolic, and infection diagnostic tests
Electronic medical record and picture archiving and communicating systems for patient-related
diagnostic and care-related information
Maternal care services

Obstetric services and maternal–fetal medicine:
management of maternal and obstetric care needs
and complications
Obstetric anesthesia: maternal management
during obstetric or fetal interventions
Adult medicine: consultation and comanagement of maternal medical conditions or
complications of pregnancy or treatment
Intensive care unit: management of maternal
critical illness related to pregnancy or treatment

Respiratory technologist or anesthetic assistant:
fetal management during interventions
Pediatric cardiology: Prenatal diagnosis and
consultation, postnatal management, fetal hemodynamic monitoring during complex procedures or
transplacental medical therapy, neonatal cardiac
care
Additional care services

Social work and spiritual support: coordination
of social services, patient advocacy
Patient services coordinator, financial counselor: scheduling of appointments, financial planning assistance, and insurance authorization across
all involved care specialties
Data coordinator: tracking and facilitating the
reporting of outcomes-related data of the fetal
therapy center
Interpreting and cultural diversity specialist:
consultation, consent, follow-up services, with
availability especially when multiple therapeutic
options are being entertained
Family planning: safe pregnancy termination
and contraception counseling
Palliative care: palliative neonatal care, perinatal hospice services
Research regulatory and ethics

Institutional research review boards: oversight
of experimental and research-related interventions
Medical ethicist: consultation and oversight as
needed for research and ethical questions that arise
during clinical care
Database and information technology support:
data collection for sharing, reporting, quality
improvement, and research
Data from Moon-Grady AJ, Baschat A, Cass D, Choolani M,
Copel JA, Crombleholme TM, et al. Fetal treatment 2017:
the evolution of fetal therapy centers - a joint opinion from
the International Fetal Medicine and Surgical Society
(IFMSS) and the North American Fetal Therapy Network
(NAFTNet). Fetal Diagn Ther 2017;42:241–8. doi: 10.1159/
000475929

Neonatal and pediatric care services

Neonatology: prenatal consultation; bridge to postnatal follow-up, neonatal care
Pediatrics: prenatal consultation, neonatal and
pediatric management
Pediatric surgery: prenatal consultation and
postdelivery management
Pediatric anesthesia: fetal management during
interventions
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care can be better provided at another facility, referral
should be considered.
Informed consent for fetal therapy is unique
because interventions for the benefit of the fetus are
performed on the pregnant individual. This emphasizes
the need for a nondirective, shared decision-making
approach that allows the pregnant individual to make
an autonomous, intentional, and voluntary choice, free
of any coercion or undue influence from family
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members, spouses, partners, or even health care
professionals themselves, to undergo or decline any
fetal therapy. A thorough discussion with patients
needs to clearly present the full range of therapeutic
options, their risks and benefits for the fetus, as well as
any potential risks to the pregnant individual in the
current or future pregnancies. An important conversation that should precede any fetal intervention, particularly in a sick or very premature fetus, is the
management of procedure-related fetal complications,
specifically addressing whether delivery or nonintervention is to be undertaken, with clear discussion of all
consequences. These conversations are best held in
collaboration with maternal–fetal medicine specialists,
neonatologists, and additional specialists as required by
the condition and may benefit from the involvement of
an unbiased and specially trained independent advocate, such as the patient’s primary health care professional, perinatal nurse, or religious advisor.29–33

UNIVERSAL CORE COMPONENTS AND
OPERATIONAL RESPONSIBILITIES OF A FETAL
THERAPY CENTER
Certain resources are fundamental to optimize the
provision of care and to minimize any fetal therapy
procedure–related risks. Universal core components
of a fetal therapy center as designated by several
professional societies are summarized in Box 1.2,5,7
The need for additional resources that may be
required for specific interventions should be considered in the context of the proposed fetal therapy
center care levels.

Leadership
A fetal therapy center should have a medical director—a
physician with experience in maternal and fetal care
and, specifically, in maternal–fetal interventions. The
medical director is responsible for operational oversight
of delivery of clinical care and ensuring patient safety.
The medical director should work in partnership with a
nursing director, who supervises the nursing staff and
shares in the oversight of patient care and center operations. Others may be appointed in allied leadership
roles, depending on the operational setup at a particular
fetal therapy center. Although fetal therapy is not a
recognized subspecialty, its practice demands advanced
understanding and training in fetal physiology; expertise
in prenatal diagnosis, fetal imaging, and surveillance;
and operative skills to safely perform fetal interventions.

Staffing
A fetal therapy center requires a multidisciplinary and
closely collaborative group of health care personnel.
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In addition to providing safe and effective fetal
therapy, a center’s team should facilitate a positive
care environment and experience by providing pregnant individuals and their families with access to
resources that facilitate managing their expectations
and coping with their stress and grief. Nurses with
expertise in fetal diagnosis and prenatal care play a
central role in fetal therapy centers and may be
involved in the patients’ and referring health care professionals’ initial contact with the center, throughout
prenatal evaluation, counseling, fetal intervention,
and follow-up.33,34 A financial counselor or insurance
specialist may assist in reviewing a patient’s health
care coverage and initiate insurance authorization if
required. A nurse coordinator or licensed social
worker may help manage the psychosocial needs of
the patient and family and act as an advocate. Geneticists and genetic counselors can refine the genetic
testing strategy, discuss results with families, and help
to arrange relevant autopsy examinations when indicated. Key members of any team are practitioners
who are skilled in performing the fetal interventions.
Other medical specialists should be involved as
required in each case. A perinatal or pediatric palliative care service is important for cases in which a fetal
death or complicated neonatal course are anticipated.
A data coordinator is invaluable in ensuring that
key indicators of care quality and outcome are
monitored and can be audited and reported to
internal and external registries, funding agencies,
and patients, as needed.2 Given the ethical challenges
entailed in certain, particularly innovative, fetal interventions, the involvement of the institutional ethics
committee in such circumstances is vital.2,28–30

Diagnostic Services
A fetal therapy center needs to have access to appropriate
diagnostic services for all conditions that they intend to
manage. This includes imaging specialists skilled in the
performance of detailed fetal ultrasonography, fetal
echocardiography and cardiovascular imaging, and magnetic resonance imaging. Imaging expertise has to include
prognostic staging for conditions such as congenital
pulmonary airway malformations,34 congenital diaphragmatic hernia,35 congenital heart disease,36,37 fetal hydrops,38 and twin–twin transfusion syndrome,39–41 as
well as ultrasonography for procedural guidance. Magnetic resonance images should be interpreted by a boardcertified imaging radiologist with specific expertise in fetal
magnetic resonance imaging. For complex cardiac conditions, a pediatric cardiologist with expertise in fetal
echocardiography and postnatal cardiac management
must be involved.

OBSTETRICS & GYNECOLOGY
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All imaging personnel should be accredited with
their respective professional membership associations,
for example, the Registry of Diagnostic Medical
Sonographers, the American Institute of Ultrasound
in Medicine, the American College of Radiology, or
the Canadian Association of Radiologists. They should
maintain their required competencies and regularly
participate in continuing medical education, which will
enhance the quality of the services they provide.42 A
fetal therapy center needs access to the full range of
genetic, microbiology, hematology, pathology, and laboratory services, with the requisite expertise to allow
the correct interpretation of fetal test results.43–47

Facilities Needed to Offer Fetal Therapy and
Maternal, Fetal, and Neonatal Care
Appropriate clinical facilities should be identified
where fetal interventions can be performed and where
postprocedure monitoring and recovery of the pregnant patient and fetus(es) can occur. Depending on the
nature of the procedure and gestational age, this may
be in the imaging facility, fetal medicine unit, operating room, or labor and delivery suite. After fetal
viability, all fetal therapy procedures should be
performed in areas with access to a labor and delivery
suite and neonatal intensive care unit (NICU). Operative and monitoring equipment needs to be available
and should be regularly serviced. The capacity for
rapid provision of red blood cells or platelets for
intrauterine transfusion as well as medications for fetal
administration are necessary at any fetal therapy
center.

Policies, Organization, Conduct,
and Governance
Fetal therapy centers should offer evidence-based
therapies that are subject to institutional oversight
and provide transparent and complete reporting of
maternal and fetal outcomes. Innovative interventions, including any that entail substantial modification to accepted protocols or procedures, should be
undertaken only with prior in-depth discussion,
review, and consensus-based approval by the relevant
subspecialists and potential consultation with an
institutional ethics committee or panel.48,49 Research
must be conducted with institutional review board
approval and oversight, including registration as a
clinical trial when appropriate. The fetal therapies that
are offered, their eligibility criteria, as well as the
mechanisms to introduce new therapies should be
clearly established at each institution and reviewed
periodically as part of a formal institutional or departmental quality-assurance process.

VOL. 139, NO. 6, JUNE 2022

For those who choose pregnancy termination, a
process should be in place to ensure access, including
referral to another accommodating practitioner or
facility if abortion services are not available at the fetal
center.50

Fetal Therapy Oversight
A multidisciplinary fetal therapy advisory committee
ideally includes representation from a variety of
health care workers, including maternal–fetal medicine specialists, pediatric surgeons, anesthesiologists,
neonatologists, geneticists, social workers, nurses,
perinatal medical ethicists, and other ad hoc members, as appropriate, who may or may not be involved
in the direct care of the patient. The composition, role,
and responsibilities of such a committee may be
modified depending on the specific needs of a fetal
therapy center and could range from quality assurance or audit through clinical oversight. Committee
members might review proposed interventions that
are considered (locally) innovative or experimental,
evaluate research proposals before their submission,
participate in trial-related data safety monitoring
boards, or conduct case reviews.

Maintenance of Competency and
Center Performance
Achieving optimal maternal and fetal outcomes is
dependent on a number of factors, including practitioner and team experience, local resources and
setting, case volume, ongoing audit, and maintenance
of competency of the whole health care team.51–53
The association between surgical volume and
improved outcomes has been attributed to multiple
factors, including team proficiency and their ability
to recognize, triage, and manage specific complications within a particular health care system.54–60
Developing relevant, agreed-on outcome measures for specific interventions that are frequently
evaluated and monitored will help to prospectively
evaluate fetal intervention risks, as well as the overall
performance of fetal therapy treatments. Outcomes
relevant for any fetal intervention include 1) preterm
prelabor rupture of membranes (PROM), preterm
birth, mode of delivery, stillbirth, or neonatal death;
2) maternal complications such as hemorrhage, infection, pulmonary edema, or intensive care unit (ICU)
admission; 3) the frequency with which the intended
treatment outcome was achieved; and 4) the effect on
future fertility and pregnancy outcomes.2–7,61 Core
outcome sets are being developed in fetal medicine
and currently exist for twins, twin–twin transfusion
syndrome, congenital diaphragmatic hernia, fetal
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myelomeningocele closure, and fetal growth restriction.6,61–64 Centers should also develop or participate
in needs-specific continuing medical education and
quality-improvement programs, which may include
the use of simulation training models, to help develop
and maintain their competence in specific fetal interventions.65–67
Downloaded from http://journals.lww.com/greenjournal by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0h
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FETAL THERAPY CENTER CARE LEVELS—
PRINCIPAL CONSIDERATIONS
A fetal therapy center needs to have all of the
resources to carry out fetal interventions and to
manage any maternal, fetal, or neonatal complications
that might arise. We are proposing a three-tiered
model to optimize the delivery of care at each level of
case complexity, which may entail regionalized concentration of some subspecialized health care services.7–11 The underlying fetal condition, type of
intervention, and expected treatment outcomes are
the primary factors determining these proposed tiers
and resource settings. Intervention-related risks can
occur independent of experience or case volume,
and, particularly, maternal complication rates tend
to be underreported.68–75 Patient safety requires a
care setting that, at the very least, can manage common (greater than 1%) as well as infrequent but severe
complications.7,75,76 The care level documents for
maternal,8 neonatal,9 and pediatric surgery10 provide
the underlying framework that was adapted for fetal
therapy centers.

Maternal Levels of Care
Aside from accredited birth centers, maternal care
settings have been stratified into four levels in the
United States. Of these, levels III (subspecialty care)
and IV (regional perinatal center) have boardcertified obstetricians, maternal–fetal medicine
subspecialists, obstetric anesthesiologists, and adult
subspecialists, with ICU facilities onsite that accept
individuals who are pregnant or in the postpartum
period; both levels III and IV allow access to the
full range of expertise that may be necessary for any
maternal or fetal intervention.8–10,76–78 Onsite ICU
care at a level IV center allows for primary or comanagement by a maternal–fetal medicine team
with expertise in complex medical conditions and
critically ill or unstable pregnant or postpartum
patients.

Neonatal Levels of Care
Within the four neonatal care levels, level III and IV
NICUs have attendant neonatologists, nurse practitioners, respiratory technologists, and pediatric anes-
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thesiology services either onsite or readily available at
an adjacent institution. Although level III NICUs can
provide prolonged support for all degrees of prematurity, the ability to provide onsite subspecialty
care, including the surgical management of complex
congenital abnormalities, is limited to level IV NICUs
or pediatric intensive care units (PICUs).9,10 Neonatal
outcomes are improved the closer the delivery occurs
to a pediatric center that can provide a full range of
medical and surgical care.79–85 All fetal interventions
that may potentially result in (iatrogenic) preterm
delivery after viability require, at least, level III NICU
support. Complex neonatal management challenges,
including those encountered with congenital anomalies, may benefit from access to a level IV NICU with
subspecialty resources.86–90 Surgical care of newborns
with congenital anomalies is optimized in the highestlevel pediatric surgery facility, which is required for
level IV NICU or PICU designation.9,10

Considerations for Selecting the Necessary
Level of Care
Before performing any fetal intervention, factors such
as gestational age; fetal condition; and procedurerelated maternal, fetal, or preterm delivery risks, as
well as the potential need to deliver outside the
patients’ community, must be evaluated to determine
whether the case can be managed locally or if transfer
to a higher-level facility should be considered. It is
important that each fetal therapy center has strong
institutional backing and that specific policies are in
place to support a collaborative, multispecialty model.

Risk Profile and Complexity of
Fetal Interventions
The overall risk profile and complexity of any fetal
intervention is related to its degree of invasiveness
and the required interventional setup. These factors
also determine the type of anesthesia or analgesia
required,, as well as the need for maternal and fetal
monitoring during and after the procedure. Neonatal
risks are determined by the potential risk of delivery
soon after the intervention, gestational age at the time
of intervention, and the neonatal management needs
specific to the fetal condition. Therefore, neonatal
care needs can range from management of prematurity to multidisciplinary management of coexisting
conditions. We propose that fetal interventions be categorized at three levels: 1) needle-based, 2) percutaneous, and 3) open or laparotomy. These levels
dictate the resource setting in which these procedures
can be performed safely.
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Ultrasonography-Guided Needle-Based Fetal
Therapy Interventions
For these procedures, a fine needle is advanced into
a target under continuous ultrasonographic guidance. This approach is used for chorionic villous
sampling, amniocentesis, amnioinfusion, amnioreduction, fetal fluid drainage, fetal blood sampling,
intrauterine transfusion of blood products,91,92
direct delivery of fetal medications,93 fetal or placental interstitial vascular occlusion,94–97 and fetal
cardiac interventions25 (Table 1). Needle-based procedures typically require only local anesthesia but
may occasionally require intravenous conscious
sedation and, very rarely, neuraxial anesthesia.98
The principal maternal risks include postprocedural
pain, preterm PROM, preterm labor, and the need
for emergent delivery for fetal distress (Table 1).
After viability, intraoperative fetal surveillance
may be used to identify any signs of compromise
that might require either intrauterine resuscitation
or delivery. After the procedure, maternal monitor-

ing for obstetric complications and fetal heart rate
monitoring after viability are performed.
Percutaneous Fetal Interventions
Percutaneous interventions include ultrasonographyguided bipolar cord coagulation,99,100 radio frequency
ablation,101 shunt procedures102–110 and fetoscopy for
laser umbilical cord occlusion,111 laser ablation of placental vascular anastomoses,112,113 fetoscopic endotracheal occlusion,114 amniotic band resection,115 and
percutaneous fetal myelomeningocele closure116–119
(Table 2). Fetoscopic interventions or bipolar forceps
procedures are performed using a combination of
ultrasonographic guidance and direct visualization,
entering the uterus directly or through a sheath. Percutaneous fetoscopic fetal myelomeningocele closure
notably may employ multiple ports. Anesthetic
requirements increase correspondingly with increasing invasiveness, procedure duration, and complexity,
from local anesthesia to conscious intravenous sedation (monitored by the anesthesiology team) to

Table 1. Ultrasonography-Guided Needle-Based Fetal Interventions
Procedure
Fetal blood sampling and
transfusion19,21,70,91,92
Needle size: 22-20
gauge (outer diameter
0.71–0.91 mm)

Reported Procedural Risks

Required Resources

Maternal: urgent delivery

Maternal: L&D unit if viable; OB anesthesiology
for intravenous conscious sedation84 or, rarely,
neuraxial anesthesia85
Fetal: puncture site bleeding 20–30%; transient
Fetal: trained intervention team, blood bank for
bradycardia 5–10%; fetal death 0.4%; up to 25%
preparation of fetal blood products,
for complicated fetal disease and hydrops
medications for fetal paralysis and
resuscitation
Neonatal: premature delivery (average gestational Neonatal: NICU if viable, with subspecialty
age at birth: 31–35 wk; condition-specific)
access for complex or severe conditions
Maternal: postoperative pain up to 32%;
Maternal: L&D unit if viable; OB anesthesiology
Fetal cardiac
postoperative nausea or vomiting up to 26%
for sedation; neuraxial, general anesthesia as
interventions25,81
Needle size 18-16 gauge
required
(outer diameter 1.27–
Fetal: transient hemopericardium 18–28%;
Fetal: multidisciplinary fetal cardiac intervention
1.65 mm)
bradycardia up to 32%; IUFD by 48 h 10–30%
team (blood bank to prepare fetal blood
products);* medication for fetal paralysis and
resuscitation
Neonatal: premature delivery (less than 37 wk up to Neonatal: NICU with pediatric cardiology or
20%); fetal death before discharge up to 61%
cardiac surgery; pediatric anesthesiology and
subspecialty access
Maternal: myometrial bleeding less than 1%
Maternal: dedicated intervention setting, OB
Radiofrequency,
anesthesiology for intravenous conscious
microwave, or
sedation and, rarely, neuraxial anesthesia;
interstitial laser
L&D unit for postprocedure monitoring
ablation95–97,100,101
Instrument size: 18-16
Fetal: miscarriage within 2 wk 3%; thermal injury of Fetal: trained intervention team
gauge (outer diameter
co-twin 2%; co-twin death 10–16%; PPROM
1.27–1.65 mm)
within 2 wk 2–9%
Neonatal: premature delivery (less than 32 wk 9– Neonatal: NICU after viability
18%; less than 37 wk 9–18%)
L&D, labor and delivery; OB, obstetric; NICU, neonatal intensive care unit; IUFD, intrauterine fetal death; PPROM, preterm prelabor
rupture of membranes.
* Not typically used but may be required on a case-by-case basis in the absence of fetal compromise.
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Table 2. Ultrasonography-Guided Shunting or Fetoscopic Fetal Interventions
Procedure

Reported Procedural Risks

Shunting procedures103–110
Instrument diameter: 6–9
French (1.83–3 mm)

Required Resources

Maternal: myometrial bleeding less than 1%
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Maternal: L&D unit if viable; OB anesthesiology
for intravenous conscious sedation or, rarely,
neuraxial anesthesia
Fetal: shunt failure or dislodgement 8–35%;
fetal: trained intervention team; medications for
Chorioamnion separation up to 7.7%; PPROM
fetal administration as required
up to 10%; fetal death up to 12%
Neonatal: premature delivery (less than 34 wk Neonatal: NICU if viable, with subspecialty
up to 56%); NICU admission up to 83%;
access as dictated by the fetal disease
neonatal death up to 22%
Maternal: trocar site bleeding 1–3%
Maternal: dedicated intervention setting; L&D
Bipolar or fetoscopic cord
unit; OB anesthesiology for intravenous
coagulation76,95–97
Instrument diameter: 1.5–
conscious sedation or neuraxial anesthesia as
5 mm
required
Fetal: co-twin death 8–14%; PPROM at less than Fetal: trained intervention team with specific
32 wk 23–34%; chorioamnion separation 5–
procedural expertise at the expected level of
10%
complexity
Neonatal: premature delivery (less than 32 wk Neonatal: NICU if viable, with subspecialty
23–34%); neonatal death 6–12%
access if more severe fetal disease is present
Maternal: pulmonary edema 1–8%; ICU
Maternal: dedicated intervention setting; L&D
Fetoscopic laser
admission 1–2%; trocar site bleeding 5–7%;
unit; OB anesthesiology for intravenous
surgery18,22,74,76,132,133
Instrument diameter: 5–12
maternal blood transfusion up to 2.9%; intraconscious sedation or neuraxial anesthesia as
French (1.5–4 mm)
abdominal fluid leakage 1–7%
required; blood bank; ICU availability
Fetal: PPROM in less than 24 h 3–4%;
Fetal: trained intervention team with specific
chorioamnion separation 5–10%; placental
procedural expertise at the expected level of
abruption 1–3%; PPROM at less than 32 wk
complexity
19–34%
Neonatal: preterm birth at less than 33 wk up to Neonatal: NICU if viable; access to pediatric
36%
cardiology for severe fetal disease
Maternal: abdominal hemorrhage 0.5%
Maternal: dedicated intervention setting; L&D
FETO76,114,120,121,134
Instrument diameter: 10
unit; OB anesthesiology for intravenous
French (3.3 mm)
conscious sedation or neuraxial anesthesia as
required; blood bank; ICU availability
Fetal: fetal death 2%; unscheduled balloon
Fetal: expertise with FETO procedure; on-call
removal up to 56%; unscheduled EXIT
multidisciplinary team for emergent balloon
procedure up to 7%
removal or EXIT procedure
Neonatal: PTB at less than 34 wk up to 31%;
Neonatal: NICU; PICU; pediatric surgery;
postnatal balloon removal up to 17%
pediatric anesthesiology; pediatric cardiology;
ECMO; pediatric ENT
Maternal: dedicated intervention setting; L&D
Maternal: pulmonary edema 2%; abdominal
Percutaneous fetoscopic
unit; OB anesthesiology for intravenous
CO2 leak 20–33%
MMC closure116–119,130
Instrument diameter 10–15
conscious sedation; neuraxial or general
French (3.3–5 mm), up to 4
anesthesia as required; blood bank; adult ICU
ports
Fetal: PPROM at less than 34 wk 67%
Fetal: fetal MFM surgeon; pediatric neurosurgery
Neonatal: PTB at less than 35 wk up to 23%;
Neonatal: NICU with subspecialty care;
CSF leakage at birth up to 32%
pediatric neurosurgery; pediatric
anesthesiology
PPROM, preterm prelabor rupture of membranes; NICU, neonatal intensive care unit; L&D, labor and delivery; OB, obstetric; ICU, intensive
care unit; EXIT, ex utero intrapartum treatment; PTB, preterm birth; FETO, fetoscopic endotracheal occlusion; PICU, pediatric intensive
care unit; ECMO, extracorporeal membrane oxygenation; ENT, ear, nose, and throat; MMC, myelomeningocele; CSF, cerebrospinal
fluid; MFM, maternal–fetal medicine.

neuraxial or general anesthesia. After these types of
procedures, surgical complications such as trocar site
bleeding, intraperitoneal amniotic fluid or CO2 leakage, and, occasionally, even pulmonary edema or
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need for ICU admission may be encountered. These
risks, as well as the potential obstetric complications
of preterm PROM and preterm labor, require maternal and fetal postprocedure monitoring on a labor and
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delivery unit, and, occasionally, access to adult ICU
services. Patients undergoing fetoscopic endotracheal
occlusion may require the emergent removal of a tracheal balloon, necessitating 24/7 availability of an ex
utero intrapartum treatment (EXIT) team in the event
that a balloon is still in situ if preterm labor occurs and
cannot be removed either by ultrasonography-guided
needle puncture or fetoscopically.114,120,121 After
delivery, neonates with spina bifida or congenital diaphragmatic hernia are likely to need management in a
level III–IV NICU or PICU.
Fetal Interventions Requiring Laparotomy
Fetal interventions requiring a maternal laparotomy
and hysterotomy (ie, “open fetal surgery”) include
open fetal myelomeningocele closure,122 resection
of fetal tumors such as a sacrococcygeal tera-

toma,123–126 and the EXIT procedure for airway
obstruction.127,128 Although open fetoscopic fetal
myelomeningocele closure avoids a hysterotomy,
the maternal laparotomy itself carries comparable
operative risks129,130 (Table 3). Open procedures
are performed under general anesthesia, aided by
neuraxial anesthesia, for intrapartum and postpartum pain management and require more sophisticated
intraoperative
maternal
and
fetal
monitoring. The procedural setup, as well as the
requisite operator and multidisciplinary team
expertise, is most demanding for these procedures,
and access to the highest level of maternal (level III
or IV) and neonatal care resources is required. After
a procedure, the pregnant patient and fetus need to
be monitored in a labor and delivery setting, with
ready access to ICU resources if needed.

Table 3. Fetal Interventions Requiring Maternal Laparotomy
Procedure

Reported Procedural Risks

Required Resources

Maternal: pulmonary edema up to 9%
Open fetoscopic MMC
closure119,129,130 (ie, with
laparotomy and fetoscopy)

Open fetal MMC closure71–
73,76 (ie, with laparotomy
and hysterotomy)
Open fetal
surgery76,119,123,126

EXIT procedures76,127,128

Maternal: dedicated intervention setting; L&D
unit; OB anesthesiology for neuraxial or
general anesthesia and postoperative pain
management as required; blood bank; adult
ICU
Fetal: PPROM at less than 37 wk up to 25–38% Fetal: fetal MFM surgeon; pediatric neurosurgery;
pediatric surgery; pediatric anesthesiology
Neonatal: premature delivery (less than 35 wk
Neonatal: NICU with subspecialty care;
45–52%); perinatal death 3–6%; dehiscence at
pediatric neurosurgery
repair site 4.3–13%
Maternal: pulmonary edema 2–6% (up to 27.8% Maternal: dedicated intervention setting; L&D
for open fetal surgeries)135
unit; OB anesthesiology for neuraxial or
Intraoperative blood transfusion 1–6% (fetal
general anesthesia and postoperative pain
myelomeningocele repair), 9–13% for other
management as required; blood bank; adult
open fetal surgery; ICU admission up to
ICU
24.6%; intubation for more than 48 h up to
2.3%
Fetal: bradycardia requiring resuscitation 5–10%; Fetal: fetal MFM surgeon; pediatric neurosurgery;
pediatric surgery; pediatric anesthesiology;
PPROM at less than 37 wk 32–46%; fetal death
fetal echocardiography; pediatric
up to 4.3%135
subspecialties
Neonatal: premature delivery (less than 35 wk
Neonatal: NICU with subspecialty care, eg,
45–52%); perinatal death 3–6%; dehiscence at
pediatric neurosurgery or other conditionrepair site in current or future pregnancies 4.3–
specific specialties
13%
Maternal: intraoperative atony and hemorrhage Maternal: dedicated intervention setting; L&D
unit; OB anesthesiology for neuraxial or
general anesthesia as required; blood bank;
adult ICU
Fetal: perinatal death 3–14%, usually attributable Fetal: multidisciplinary intervention team
to primary pathology
Neonatal: premature delivery (average
Neonatal: NICU with subspecialty care
gestational age 31–36 wk)

MMC, myelomeningocele; PPROM, preterm prelabor rupture of membranes; L&D, labor and delivery; OB, obstetric; ICU, intensive care
unit; MFM, maternal–fetal medicine; NICU, neonatal intensive care unit.
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PROPOSED LEVELS OF CARE FOR FETAL
THERAPY CENTERS
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The care level of a fetal center is defined by the
presence of resources tailored to the level of complexity of the intervention and ability to manage
anticipated maternal, fetal, and neonatal complications. Based on the complexity and risk profile of fetal
interventions, three levels of fetal care are proposed.

Level I
A level I fetal therapy center should be capable of
offering fetal interventions that may be associated
with the obstetric risks of preterm PROM and preterm
birth but that would be very unlikely to require
maternal medical subspecialty or ICU care (Box 2).
Neonatal risks should not exceed those of moderate
prematurity (ie, 32–37 weeks of gestation),131 and a

neonate should be unlikely to require any subspecialty medical or surgical care. Maternal care
resources should meet ACOG–SMFM level III
obstetric care center standards, and the NICU should
be level III. After a procedure, maternal and fetal
monitoring should be supervised by the maternal–
fetal medicine team members of the fetal therapy
center. In experienced hands, needle-based procedures and transplacental medical therapy can be performed at a level I fetal therapy center (Box 2). After
viability, interventions carrying a risk for fetal distress
should be performed with ready access to a labor and
delivery unit and NICU. If any procedure is felt to be
beyond the expertise of the local practitioners, or if
the local supportive care resources are insufficient,
referral to an institution where these needs can be
met should be initiated if feasible.

Box 2. Proposed Fetal Therapy Levels and Specific Resource Setting
Level I
Definition: fetal therapies with low maternal and fetal risk
Personnel: fetal therapy center team, supported by institutional infrastructure
Maternal care level: at least level III
NICU care level: at least level III
Examples of procedures: fetal blood sampling, uncomplicated IUT, fetal shunt placement, radiofrequency or
interstitial laser ablation, fetal antiarrhythmic treatment*
Additional consideration: mechanism in place to evaluate case complexity before interventions and transfer care
to a higher level fetal therapy center if required
Level II
Definition: fetal therapies with low or high maternal risk but low neonatal risks
Personnel: fetal therapy center team, supported by institutional infrastructure
Maternal care level: at least level III
NICU care level: at least level III
Pediatric surgery care level: level I for all conditions for which a fetal intervention is offered
Examples of procedures: all procedures performed at level I centers, plus complicated IUT,† fetoscopic laser
ablation for TTTS, ultrasonography-guided cord or vascular occlusions, fetoscopic amniotic band resection, fetal cardiac interventions,‡ uncomplicated EXIT procedures§
Level III
Definition: all fetal therapies, irrespective of their risk level
Personnel: fetal therapy center team, supported by institutional infrastructure
Maternal care level: at least level III
NICU care level: level IV
Pediatric surgery: level I for all conditions
Examples of procedures: all procedures performed at level I and II centers irrespective of the level of fetal compromise or
procedural challenge, plus FETO balloon placement and retrieval, complex multidisciplinary fetoscopic
procedures, open fetal surgery, 24/7 availability of EXIT procedures
NICU, neonatal intensive care unit; IUT, intrauterine transfusion; TTTS, twin–twin transfusion syndrome; EXIT, ex utero intrapartum
treatment; FETO, fetoscopic tracheal occlusion.
*Maternal digoxin, sotalol, flecainide, or amiodarone treatment should be undertaken with input from and neonatal follow-up with a
fetal–pediatric cardiology specialist.
†Complicated IUT refers to procedures performed at less than 20 weeks of gestation or in the presence of a compromised or hydropic
fetus or with high maternal body mass index.
‡To be undertaken only if disease-specific pediatric care services are present, ideally at that institution or else by remote virtual
consultation.
§Uncomplicated EXIT procedures refers to procedures that can be scheduled electively, well in advance, and for which all required
resources are available.
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A level II fetal therapy center should be capable of
offering fetal interventions that also carry risks that
might necessitate maternal ICU admission or could
result in very preterm birth after viability (Box 2).
Although most level II fetal centers will be capable
of managing the majority of maternal risks associated
with any particular fetal intervention, the pediatric
specialty resources to manage some of the more challenging neonatal issues may not be immediately available. Maternal care resources should comply with
ACOG–SMFM level III or IV obstetric care center
standards, but a level III NICU is sufficient (Box 2).
Level II fetal care centers should be capable of offering the full range of procedures performed at a level I
center but could also manage more complex
ultrasonography-guided procedures and fetoscopies
as well pregnant patients with comorbid conditions
or high BMIs (Box 2). After viability, fetal therapy
should be offered only for conditions for which the
appropriate level of neonatal care is available. A level
II center might, on a case-by-case basis, be capable of
performing a prescheduled EXIT procedure, presuming onsite availability of the relevant pediatric airway
expertise.

Level III
A level III fetal therapy center can offer the full range
of minimally invasive and open fetal interventions
and can manage all levels of maternal and neonatal
risk or complications that might be encountered with
such procedures (Box 2). These centers will have level
III or IV maternal care services, with ready access to a
level IV NICU or PICU with the full range of pediatric subspecialties. A level IV maternal care center
allows co-management or close collaboration between
ICU and maternal–fetal medicine subspecialists. A
level III fetal center can offer the complete range of
fetal therapy, including all therapies offered at level I
and II centers, fetoscopic endotracheal occlusion for
congenital diaphragmatic hernia, and all open fetal
surgical procedures. It can also manage fetal conditions such as compromised congenital pulmonary
airway malformations, fetal hydrops, congenital diaphragmatic hernia, and spina bifida. The center
should also have the capability to rapidly assemble
complex medical teams on a 24/7 basis (eg, for
EXIT).132

and autonomy while also optimizing fetal, neonatal,
and maternal outcomes. The fetal interventions
offered should reflect the available expertise,
resources, and degree of institutional support. This
document proposes three levels of care for fetal
therapy centers. Our intention is to provide guidance
for the optimal care setting in which fetal interventions can be offered. Multidisciplinary care is fundamental to the establishment and operation of a fetal
therapy center. The proposed fetal levels of care are
aligned with existing levels of care for maternal,
neonatal, and surgical care. In the absence of any
central, national, or international regulatory body at
present, it is the responsibility of the leadership at
each fetal therapy center to ensure appropriate staff
credentialing, resource planning, quality benchmarking, and outcome reporting for any intervention
offered at that institution. This document is intended
as a guide for the optimal resources that ought to be in
place to facilitate fetal therapy. It is not intended to
impede the development of new fetal centers, but
rather to assist them in considering the necessary
components to ensure patient safety and procedural
success. As the technology, instrumentation, and
procedures in fetal therapy evolve, different resources
may be suggested. The overarching goal is continued
advancement of fetal therapy through provision of
safe and effective treatment of fetal disease.
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